Why Hims & Hers Stock’s Recent Dip Might Be a Great Investment Opportunity

In partnership with

Take a demo, get a Blackstone Griddle

Financial operations heating up? BILL Spend & Expense can help you take control. Automate expense reports, set budgets across teams, and get real-time insights into company spend. Take a demo to learn how and we'll give you a 28" Blackstone Omnivore Griddle—so you can take control of your next barbecue, too.

Request a demo

Market conditions have grown increasingly challenging lately, and former high-flying stocks have suffered big losses. Nvidia ($NVDA), the poster child of the AI hype rally, is officially in a bear market, down 25% from its highs. Another high-flying name that has seen a significant drop in recent weeks is Hims & Hers ($HIMS).

At one point earlier this year, HIMS stock was up as much as 200%. But since hitting all-time highs in June, HIMS has lost a third of its value, due to the overall market rout and investor overreaction to news. On Monday, the company reported Q2 earnings that beat analyst estimates across the board and raised its full-year outlook, yet the stock tumbled 5%.

It’s an odd reaction that doesn’t make sense, considering HIMS’ solid fundamental performance. However, as you can see above, the stock is still in a clear uptrend, which can continue as the company is firing on all cylinders. New product launches in the weight loss and other spaces are accelerating the company’s growth while profitability is soaring, underscoring the company’s successful growth strategy. The recent dip seems like a great buying opportunity in one of the most promising health-tech names on the market. Let’s take a deeper dive.

Subscribe to Premium Membership to read the rest.